Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Short term Debt (2020 - 2025)

Candel Therapeutics' Short term Debt history spans 2 years, with the latest figure at $8.9 million for Q4 2023.

  • On a quarterly basis, Short term Debt changed N/A to $8.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $8.9 million, a N/A change, with the full-year FY2023 number at $8.9 million, changed N/A from a year prior.
  • Short term Debt hit $8.9 million in Q4 2023 for Candel Therapeutics, up from $6.1 million in the prior quarter.
  • Over the last five years, Short term Debt for CADL hit a ceiling of $8.9 million in Q4 2023 and a floor of $463000.0 in Q4 2020.